PGDx secures FDA clearance for tumor genomic profiling kit

LabPulse.com staff writers
Apr 27, 2020
2019 05 28 19 27 1157 Approved Stamp 400

Personal Genome Diagnostics (PGDx) has garnered U.S. Food and Drug Administration (FDA) clearance for its elio tissue complete genomic profiling diagnostic kit for cancer.

With the FDA clearance, molecular laboratories can now use the next-generation sequencing diagnostic kit to perform broad tumor profiling, according to the vendor. The test detects complete single nucleotide variants (SNVs) and small insertions and deletions (indels) in more than 500 genes, select amplifications and translocations, and genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB), PGDx said. Data analysis is automated.

The company's regulatory filing for the test included data from multiple lab sites, with samples from 35 tumor types.

Latest in FDA Clearance
Syphilis Treponema Bacteria Social
NowDiagnostics at-home syphilis test gets boost from Labcorp agreement
October 10, 2024
Influenza B virus particles, colorized blue, via National Institute of Allergy and Infectious Diseases (NIAID).
FDA greenlights first non-EUA at-home flu and COVID-19 test
October 8, 2024
Body composition in patients treated with Ozempic
Sponsored
Body composition in patients treated with Ozempic
September 20, 2024
Sepsis Bacteria Social
BioMérieux receives 510(k) certification for antimicrobial testing system
August 21, 2024
Related Stories
Artificial Intelligence Ai Data
Artificial Intelligence
GTC reports on validation of targeted transcriptome algorithms for diagnostic use
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400
Payor Coverage
PGDx receives updated Medicare rate for Elio test
2019 04 22 23 41 4967 Cancer Cell Target2 400
Pathology, histology
PGDx raises $103M in financing
Body composition in patients treated with Ozempic
Sponsor Content
Body composition in patients treated with Ozempic
More in FDA Clearance
NowDiagnostics at-home syphilis test gets boost from Labcorp agreement
By LabPulse.com staff writers
STI National Strategic Plan aims to reverse recent rise of STIs.
October 10, 2024
Syphilis Treponema Bacteria Social
FDA greenlights first non-EUA at-home flu and COVID-19 test
By LabPulse.com staff writers
Healgen Scientific's test targets proteins from both SARS-CoV-2 and flu A and B, plus updated FDA test listings.
October 8, 2024
Influenza B virus particles, colorized blue, via National Institute of Allergy and Infectious Diseases (NIAID).
FDA clears marketing T2 Biosystems Candida test for pediatrics
By LabPulse.com staff writers
T2Candida Panel may get a boost.
September 16, 2024
Candida Candidiasis Social
BioMérieux receives 510(k) certification for antimicrobial testing system
By LabPulse.com staff writers
BioMérieux has received 510(k) clearance from the U.S. Food and Drug Administration for its Vitek Reveal AST system, which reports antimicrobial susceptibility testing (AST) results directly from positive blood cultures.
August 21, 2024
Sepsis Bacteria Social
NowDiagnostics granted FDA marketing authorization for OTC syphilis test
By LabPulse.com staff writers
NowDiagnostics has been granted de novo marketing authorization from the U.S. Food and Drug Administration (FDA) for its First To Know over-the-counter (OTC) syphilis test.
August 16, 2024
Treponema pallidum, the bacteria that cause syphilis.
Thermo Fisher gets FDA 510(k) clearance for HLA typing CDx
By LabPulse.com staff writers
Thermo Fisher's SeCore CDx HLA A Sequencing System has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use as a companion diagnostic (CDx) with Adaptimmune's T-cell receptor therapy Tecelra for synovial sarcoma.
August 7, 2024
Fda Sign Dc Social
Labcorp gets FDA de novo authorization for solid tumor mutation liquid biopsy test
By LabPulse.com staff writers
Labcorp has received de novo marketing authorization from the U.S. Food and Drug Administration (FDA) for its PGDx Elio Plasma Focus Dx kitted assay, a pan-solid tumor liquid biopsy test that enables tumor mutation profiling.
August 5, 2024
Fda Button Social
Thermo Fisher Scientific gets FDA 510(k) clearance for multiple myeloma precursor assays
By LabPulse.com staff writers
Thermo Fisher Scientific received an extended 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Optilite Freelite assays for evaluating monoclonal gammopathy of undetermined significance, a precursor to multiple myeloma.
July 29, 2024
Multiple Myeloma Social
Diasorin C. auris test gets FDA de novo authorization
By LabPulse.com staff writers
Diasorin has received de novo authorization from the U.S. Food and Drug Administration (FDA) for its test kit for Candida auris, a multidrug-resistant fungal pathogen common in healthcare settings.
July 16, 2024
Candida 3 D Social
FDA approves Lilly’s Alzheimer’s disease treatment
By LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Kisunla (donanemab) for the treatment of Alzheimer’s disease.
July 3, 2024
Amyloid Plaque Alzheimer2 Social
FDA greenlights BioMérieux's mini respiratory, sore throat panel for POC testing
By LabPulse.com staff writers
BioMérieux received special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Biofire Spotfire Respiratory/Sore Throat (R/ST) Panel Mini respiratory viral and bacterial testing device designed for point-of-care (POC) testing.
June 28, 2024
Business Regulation Graphic Social Resized
FDA grants 510(k) clearance to Genetic Signature for parasitic GI infection kit
By LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Genetic Signature's EasyScreen Gastrointestinal Parasite Detection Kit and GS1 automated molecular workflow.
June 7, 2024
Lab Petri Microbiology Social
Page 1 of 8
Next Page